Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 13,791 matching trials from the live ClinicalTrials.gov search.

Filters: Dallas, Texas Clear all

Conditions: Lymphoma
Interventions: HMPL-689; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Anaheim, California • Oxnard, California • Atlanta, Georgia + 6 more

Conditions: Adjunctive Treatment of Major Depressive Disorder
Interventions: Pimavanserin, Placebo; Drug · Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 36
States / cities: Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more

Conditions: Asthma
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 30
States / cities: Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 26 more

Conditions: Care Partners of Patients With Traumatic Brain Injury (TBI)
Interventions: Problem Solving Training (PST), Education; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: East Hanover, New Jersey • Edison, New Jersey • Dallas, Texas

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: Lumateperone high dose, Lumateperone low dose, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 41
States / cities: Little Rock, Arkansas • Sacramento, California • Sherman Oaks, California + 32 more

Conditions: Renal Cell Carcinoma
Interventions: Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection, Adjuvant Pembrolizumab; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hidradenitis Suppurativa
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 59
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 51 more

Conditions: Allergy, Peanut
Interventions: DBV712, Placebo; Drug · Other
Lead sponsor: DBV Technologies; Industry
Eligibility: 4 Years to 7 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more

Conditions: Pulmonary Arterial Hypertension
Interventions: ubenimex, placebo; Drug · Other
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 28
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 22 more

Conditions: Pharmacokinetics
Interventions: Milademetan, Itraconazole, Posaconazole; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cardiovascular Disease
Interventions: Febuxostat, Allopurinol; Drug
Lead sponsor: Takeda; Industry
Eligibility: 50 Years and older
Enrollment: 6,198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 202
States / cities: Decatur, Georgia • Dunwoody, Georgia • Marietta, Georgia + 199 more

Conditions: Heart Failure, Congestive
Interventions: Levosimendan; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 132
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more

Conditions: Adrenocortical Carcinoma
Interventions: OSI-906, Placebo; Drug · Other
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 14
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Endometrial Neoplasms
Interventions: Paclitaxel, Sapanisertib, MLN1117; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • Greenbrae, California + 17 more

Conditions: Tinea Pedis
Interventions: Naftifine hydrochloride 2%, Placebo, Naftin® 2% (Naftifine hydrochloride 2%); Drug
Lead sponsor: Genzum Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 12
States / cities: Brandon, Florida • Miami, Florida • Miramar, Florida + 6 more

Conditions: Lung Cancer
Interventions: hypofractionated radiation therapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 2
States / cities: Stanford, California • Dallas, Texas

Conditions: Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Interventions: Avelumab, Oxaliplatin, 5-Fluorouracil, Leucovorin, Capecitabine, Best supportive care; Drug · Other
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 35
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more

Conditions: Fabry Disease
Interventions: PRX-102 (pegunigalsidase alfa); Biological
Lead sponsor: Protalix; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 5
States / cities: Gainesville, Florida • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: CJC-1134-PC Injection, Weekly placebo for CJC-1134-PC Injection; Drug
Lead sponsor: ConjuChem; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 19
States / cities: Phoenix, Arizona • Inglewood, California • Tarzana, California + 16 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Questionnaire Administration, Temozolomide; Drug · Procedure · Radiation + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 70 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 418
States / cities: Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more

Conditions: MPN (Myeloproliferative Neoplasms)
Interventions: Ruxolitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 88
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Baldwin Park, California + 85 more

Conditions: Relapsed/Refractory Mantle Cell Lymphoma
Interventions: brexucabtagene autoleucel, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 24
States / cities: Gilbert, Arizona • Duarte, California • Santa Monica, California + 20 more

Conditions: Surgical Procedures, Operative
Interventions: Dexmedetomidine, Remifentanil, Bupivacaine, Ropivacaine; Drug
Lead sponsor: Murdoch Childrens Research Institute; Other
Eligibility: 1 Month to 12 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Cincinnati, Ohio • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Wound Healing
Interventions: GSK1278863, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more

Search by objective public record fields.

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

Problem Solving Training for Care Partners of Adults With Traumatic Brain Injury

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

BE Study of Naftifine HCL

Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Extension Study of PRX-102 for up to 60 Months

Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

The T REX Pilot Study: a Study to Investigate the Use of an Alternative Anaesthetic in Infants.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863